ClinicalTrials.gg
CompletedNCT02009085Updated Feb 19, 2018

Pilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.

An observational study in Skin Lesions, sponsored by Orlucent, Inc. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-19.

Sponsored by Orlucent, Inc · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
126
Ages
18 Years and older
Sex
All
01

Study summary

In this study a fluorescent contrast dye is applied to a suspicious skin lesion.

Images are acquired and processed. The information is used to develop a prediction model for the presence of malignant transformation in the skin.

Read the detailed description

Images acquired in the study are used for the development of a software analysis program.

02

Conditions studied

  • Skin Lesions
03

In context

Lead sponsor

Orlucent, Inc is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients above 18 years scheduled for a skin biopsy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over the age of 18
  • Individual is scheduled for a skin in toto
  • The lesion is pigmented or non pigmented
  • Lesions may be under suspicion for basal cell carcinoma, squamous cell carcinoma, actinic keratosis, nevi, melanoma, seborrheic keratosis.
  • The lesion is accessible to the imaging device

Exclusion criteria

Exclusion Criteria:

  • The patient has sensitive skin and easily breaks out in rash
  • The lesion is within 1 cm of the eye
  • The lesion is on mucosal surfaces (e.g., lips, genitals)
  • Pregnant females
  • Taking medications that pigments the skin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
126 participants (actual)
Patient registry
No

Groups and cohorts

  • Individuals undergoing skin excision.

    Skin lesions are under suspicion for skin cancer.

06

What researchers measure

Primary outcomes

  1. Correlation between imaging and pathology.

    Patients are imaged and then undergo a biopsy. Images are used to develop a software predicting model based on pathology. Sensitivity and specificity parameters are calculated. No long term follow up is required since the biopsy is performed on the skin imaged. The follow up required is for the pathology for the skin excised.

    Time frame: No long term follow up is necessary.

Secondary outcomes

  1. Acute response

    The acute dermal response to the imaging procedure is evaluated.

    Time frame: up to 1 day

Other outcomes

  1. None specified.

    no other outcome is specified in the .

    Time frame: 0

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2013
First posted
Dec 11, 2013
Start
Jun 2013
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Last update
Feb 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02009085
Lead sponsor
Orlucent, Inc
Collaborators
Clalit Health Services
Responsible party
Sponsor
First posted
Dec 11, 2013
Start date
Jun 2013
Primary completion
Jun 2017
Completion
Jun 2017
Last update
Feb 19, 2018

Study contacts

Yehuda Ullmann, MD
principal investigator · Rambam Health Care Campus

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion